CEL-SCI Corporation
Virginia, United States · Biotechnology, Healthcare, Health Care
CEL-SCI is a clinical-stage biotechnology company focused on finding the best way to activate the immune system to fight cancer and infectious diseases. The Company’s lead investigational therapy Multikine completed a pivotal Phase 3 clinical trial involving head and neck cancer, for which the Company has received Orphan Drug Status from the FDA. The Company will be commencing a confirmatory trial
Key facts
- Headquarters
- Virginia, United States
- Employees
- 43
- Industries
- Biotechnology, Healthcare, Health Care
- Status
- Public (CVM)
- Website
- cel-sci.com
- Company page
Recent activity at CEL-SCI Corporation
- : SEC 8-K (1.01): On June 14, 2026, CEL-SCI Corporation entered into a Placement Agency Agreement with ThinkEquity LLC for the sale of 2,500,000 shares of common stock at $1.00 per share. The Offering closed on June 16, 2026, resulting in gross proceeds of $2,500,000. The funds will be used for the development of Multikine, corporate purposes, and working capital. The agreement includes a 7.0% cash fee to the Placement Agent and conditions restricting the issuance of shares for 30 days from the closing date, along with lock-up agreements from directors and officers for 45 days. The Placement Agency Agreement contains standard provisions including indemnification and termination clauses.
- : SEC 8-K (1.01): On June 14, 2026, CEL-SCI Corporation entered into a Placement Agency Agreement with ThinkEquity LLC to sell 2,500,000 shares of its common stock at an offering price of $1.00 per share. The Offering was closed on June 16, 2026, resulting in gross proceeds of $2,500,000 before deductions for fees and expenses. The proceeds are intended for the development of Multikine, general corporate purposes, and working capital. This transaction represents a significant step in funding the Company’s operational strategies and future projects.
- : CEL-SCI Corporation Raises $2.5 Million in Recent Offering
- : SEC 8-K (1.01): On May 11, 2026, CEL-SCI Corporation entered into a strategic partnership, distribution, and revenue sharing agreement with Amarox concerning regulatory affairs, marketing, and potential commercialization of Multikine for the treatment of head and neck cancer in Saudi Arabia. This agreement includes an optional extension to expand efforts into the Gulf Cooperation Council (GCC) countries, which encompass Bahrain, Kuwait, Oman, Qatar, and the United Arab Emirates. The press release indicating this significant partnership was also filed on the same date, highlighting its strategic implications for market expansion and potential revenue from the GCC region.
- : SEC 8-K (1.01): On May 11, 2026, CEL-SCI Corporation entered into a Placement Agency Agreement with ThinkEquity LLC for the sale and issuance of 6,000,000 shares of common stock at $1.20 per share, resulting in gross proceeds of $7,200,000. The offering closed on May 13, 2026, and the funds will be used for the continued development of Multikine, general corporate purposes, and working capital. The agreement includes a 7% cash fee to the Placement Agent and outlines conditions such as a 30-day period where the Company cannot issue additional securities. Directors and officers are also restricted from selling shares for a period of 45 days from May 11, 2026. This strategic move highlights CEL-SCI's commitment to advancing its projects while managing shareholder interests effectively.
- : CEL-SCI Partners with Amarox for the Distribution and Revenue Sharing of Multikine in Saudi Arabia.
- : CEL-SCI Corporation Enters Partnership with Saudi Pharmaceutical Company for Cancer Drug Multikine.
- : CEL-SCI Corporation Announces Strong Biological Rationale for Multikine in Head and Neck Cancer Study
- : CEL-SCI Renews Partnership with Ergomed for FDA Registration Study of Multikine in Head and Neck Cancer
- : CEL-SCI Corporation raised $10.8 million in a debt financing offering led by ThinkEquity to fund the continued development of Multikine and for working capital.
CEL-SCI Corporation funding history
| Date | Round | Amount |
|---|---|---|
| Jun 2026 | Post-IPO Equity | $2.5M |
| Jul 2024 | Debt Financing | $10.8M |
| Jul 2017 | Venture | Undisclosed |
Leadership
- Bruno Bailavoine, Director
- Peter Young, Director
- Alexander Esterhazy, Director
- Daniel Zimmerman, Vice President
- Eyal Talor, Chief Scientific Officer
- John Cipriano, Executive Officer
- Daniel Zimmerman, Executive Officer
- Eyal Talor, Executive Officer
- Patricia Prichep, Executive Officer
- Geert Kersten, Executive Officer
Verified email and direct lines for CEL-SCI Corporation’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Employee benefit plans
CEL-SCI Corporation files 2 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
CEL-SCI Corporation in the news
- CEL-SCI Invited to Deliver Keynote Address on Multikine at 6th World Congress on Otology, Rhinology and Laryngology - Yahoo Finance (Sep 15, 2026)
- CEL-SCI and Saudi Amarox to Conduct Signing Ceremony at BIO 2026 for Strategic Agreement to Advance Commercialization and Distribution of Multikine® in Saudi Arabia - Investing News Network (Jun 12, 2026)
- CEL-SCI Corporation Announces Pricing of Offering - Business Wire (Jun 14, 2026)
- CEL-SCI to Launch FDA Registration-Enabling Phase 3 Confirmatory Study to Bring Multikine® to Market for Newly Diagnosed Head and Neck Cancer - Yahoo Finance (Jul 13, 2026)
- CEL-SCI Reports Fiscal 2025 Results - Investing News Network (Dec 29, 2025)
- Leukocyte Interleukin Confirmatory Study Launches in Head and Neck Cancer - CancerNetwork (Jul 13, 2026)
- CEL-SCI and Saudi Amarox Hold Strategic Agreement Signing Ceremony at BIO 2026, Advancing U.S.–Saudi Cooperation in Cancer Care - Business Wire (Jun 24, 2026)
- Dr. Giovanni Selvaggi, Who Has Brought Several Oncology Drugs to Market, Joins CEL-SCI as Clinical Advisor - BioSpace (Jun 06, 2024)
Companies similar to CEL-SCI Corporation
- Vektor Medical · Biotechnology, Healthcare, Health Care
- SpyGlassPharma · Biotechnology, Healthcare, Health Care
- ImmersiveTouch · Biotechnology, Healthcare, Health Care
- Shape Memory Medical · Biotechnology, Healthcare, Health Care
- ETON PHARMACEUTICALS · Biotechnology, Healthcare, Health Care
About CEL-SCI Corporation: questions and answers
What does CEL-SCI Corporation do?
CEL-SCI is a clinical-stage biotechnology company focused on finding the best way to activate the immune system to fight cancer and infectious diseases. The Company’s lead investigational therapy Multikine completed a pivotal Phase 3 clinical trial involving head and neck cancer, for which the Company has received Orphan Drug Status from the FDA. The Company will be commencing a confirmatory trial
Where is CEL-SCI Corporation headquartered?
CEL-SCI Corporation is headquartered in Virginia, United States.
How many employees does CEL-SCI Corporation have?
CEL-SCI Corporation has about 43 employees.
Has CEL-SCI Corporation raised funding?
Yes. Fundz has recorded 3 funding events for CEL-SCI Corporation. The most recent, Post-IPO Equity of $2.5M, was in Jun 2026.
Who leads CEL-SCI Corporation?
Daniel Zimmerman is a Vice President at CEL-SCI Corporation.
What is the latest news on CEL-SCI Corporation?
On Jun 16, 2026, SEC 8-K (1.01): On June 14, 2026, CEL-SCI Corporation entered into a Placement Agency Agreement with ThinkEquity LLC for the sale of 2,500,000 shares of common stock at $1.00 per share. The Offering closed on June 16, 2026, resulting in gross proceeds of $2,500,000. The funds will be used for the de
Is CEL-SCI Corporation a public company?
Yes. CEL-SCI Corporation is publicly traded under the ticker CVM.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy